SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2677)1/24/2001 9:30:54 PM
From: John Metcalf  Respond to of 52153
 
Of the programs Wilder mentioned, I only found information that Vertex' VX475 is in the clinic. According to their website, they commenced a Phase II trial in Jan '00.



To: Miljenko Zuanic who wrote (2677)1/24/2001 9:44:09 PM
From: keokalani'nui  Respond to of 52153
 
MZ. No solid stuff. Sorry. But I only searched p53 AND arthritis. There's a 'lot' of development/compound work published that sounds like "we're doing it too", and some of it dates back a few years. Even so, not even much rodent work published. Those big pharmas do like to run silent, don't they.

I saw a list of RA treatments in human trials from almost a year ago, and I think vx-745 was the only p53 one on the list. Not very solid I'm afraid.

--Wilder


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News